Literature DB >> 27956385

Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma.

Jonathon B Cohen1, Madhusmita Behera1, Carrie A Thompson2, Christopher R Flowers1.   

Abstract

Up to 50% of patients with Hodgkin lymphoma and diffuse large B-cell lymphoma will relapse, requiring additional therapy. Although surveillance imaging is commonly performed in clinical practice, its ability to identify asymptomatic relapses and improve survival for patients is not well defined. We evaluated the surveillance imaging role in relapse detection and reviewed its impact on survival for relapsed patients, and found that current imaging approaches do not detect most relapses prior to clinical signs and symptoms or improve survival.
© 2017 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2016        PMID: 27956385      PMCID: PMC5290981          DOI: 10.1182/blood-2016-08-685073

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

1.  Late relapse in patients with diffuse large B-cell lymphoma.

Authors:  Julie M Vose; Dennis D Weisenburger; Fausto R Loberiza; Alejandro Arevalo; Martin Bast; Joel Armitage; Philip J Bierman; Robert G Bociek; James O Armitage
Journal:  Br J Haematol       Date:  2010-09-29       Impact factor: 6.998

2.  Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease.

Authors:  G Jerusalem; Y Beguin; M F Fassotte; T Belhocine; R Hustinx; P Rigo; G Fillet
Journal:  Ann Oncol       Date:  2003-01       Impact factor: 32.976

3.  Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study.

Authors:  Mark Roschewski; Kieron Dunleavy; Stefania Pittaluga; Martin Moorhead; Francois Pepin; Katherine Kong; Margaret Shovlin; Elaine S Jaffe; Louis M Staudt; Catherine Lai; Seth M Steinberg; Clara C Chen; Jianbiao Zheng; Thomas D Willis; Malek Faham; Wyndham H Wilson
Journal:  Lancet Oncol       Date:  2015-04-01       Impact factor: 41.316

4.  Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study.

Authors:  Tarec Christoffer El-Galaly; Lasse Hjort Jakobsen; Martin Hutchings; Peter de Nully Brown; Herman Nilsson-Ehle; Elisabeth Székely; Karen Juul Mylam; Viktoria Hjalmar; Hans Erik Johnsen; Martin Bøgsted; Mats Jerkeman
Journal:  J Clin Oncol       Date:  2015-10-05       Impact factor: 44.544

5.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Authors:  Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

6.  High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database.

Authors:  Gregory A Abel; Ann Vanderplas; Maria A Rodriguez; Allison L Crosby; Myron S Czuczman; Joyce C Niland; Leo I Gordon; Michael Millenson; Andrew D Zelenetz; Jonathan W Friedberg; Ann S LaCasce
Journal:  Leuk Lymphoma       Date:  2012-02-03

7.  Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy.

Authors:  U Petrausch; P Samaras; S R Haile; P Veit-Haibach; J D Soyka; A Knuth; T F Hany; A Mischo; C Renner; N G Schäefer
Journal:  Ann Oncol       Date:  2010-02-05       Impact factor: 32.976

8.  Computed tomography and positron emission tomography/computed tomography surveillance after combined modality treatment of supradiaphragmatic Hodgkin lymphoma: a clinical and economic perspective.

Authors:  Vatsal Patel; Michael Buckstein; Rodolfo Perini; Christine Hill-Kayser; Jakub Svoboda; John P Plastaras
Journal:  Leuk Lymphoma       Date:  2013-02-12

9.  Symptom-oriented clinical detection versus routine imaging as a monitoring policy of relapse in patients with diffuse large B-cell lymphoma.

Authors:  Junshik Hong; Ji Hyun Kim; Kyoung Hwa Lee; Hee Kyung Ahn; Sanghui Park; Sun Jin Sym; Jinny Park; Eun Kyung Cho; Dong Bok Shin; Jae Hoon Lee
Journal:  Leuk Lymphoma       Date:  2014-03-07

10.  Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia.

Authors:  Greg Hapgood; Yvonne Zheng; Laurie H Sehn; Diego Villa; Richard Klasa; Alina S Gerrie; Tamara Shenkier; David W Scott; Randy D Gascoyne; Graham W Slack; Christina Parsons; James Morris; Tom Pickles; Joseph M Connors; Kerry J Savage
Journal:  J Clin Oncol       Date:  2016-06-06       Impact factor: 44.544

View more
  10 in total

Review 1.  The Emerging Role of Liquid Biopsies in Lymphoproliferative Disorders.

Authors:  Jennifer Crombie; Philippe Armand
Journal:  Curr Hematol Malig Rep       Date:  2019-02       Impact factor: 3.952

Review 2.  Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma.

Authors:  R Andrew Harkins; Andres Chang; Sharvil P Patel; Michelle J Lee; Jordan S Goldstein; Selin Merdan; Christopher R Flowers; Jean L Koff
Journal:  Expert Rev Hematol       Date:  2019-09-12       Impact factor: 2.929

3.  Evolution of lymphoma staging and response evaluation: current limitations and future directions.

Authors:  Joel Cunningham; Sunil Iyengar; Bhupinder Sharma
Journal:  Nat Rev Clin Oncol       Date:  2017-06-13       Impact factor: 66.675

Review 4.  Optimizing the management of chronic pain in sickle cell disease.

Authors:  Ifeyinwa Osunkwo; Hazel F O'Connor; Elna Saah
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

5.  Cumulative Doses of Ionizing Radiation From Computed Tomography: A Population-Based Study.

Authors:  Konrad H Stopsack; James R Cerhan
Journal:  Mayo Clin Proc       Date:  2019-06-24       Impact factor: 7.616

6.  A population-based multistate model for diffuse large B-cell lymphoma-specific mortality in older patients.

Authors:  Çağlar Çağlayan; Jordan S Goldstein; Turgay Ayer; Ashish Rai; Christopher R Flowers
Journal:  Cancer       Date:  2019-02-01       Impact factor: 6.860

7.  Impact of Surveillance Imaging Modality on Survival After Recurrence in Patients With Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.

Authors:  Elizabeth A Mullen; Yueh-Yun Chi; Emily Hibbitts; James R Anderson; Katarina J Steacy; James I Geller; Daniel M Green; Geetika Khanna; Marcio H Malogolowkin; Paul E Grundy; Conrad V Fernandez; Jeffrey S Dome
Journal:  J Clin Oncol       Date:  2018-10-18       Impact factor: 44.544

8.  Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials.

Authors:  M J Maurer; T M Habermann; Q Shi; N Schmitz; D Cunningham; M Pfreundschuh; J F Seymour; U Jaeger; C Haioun; H Tilly; H Ghesquieres; F Merli; M Ziepert; R Herbrecht; J Flament; T Fu; C R Flowers; B Coiffier
Journal:  Ann Oncol       Date:  2018-08-01       Impact factor: 32.976

9.  Evaluation of latent membrane protein 1 and microRNA-155 for the prognostic prediction of diffuse large B cell lymphoma.

Authors:  Xue Wu; Fei Wang; Yuan Li; Xiyong Wang; Ping Liu; Haijun Zhang; Zheng Ge; Xiaoping Zhang; Chong Gao; Baoan Chen
Journal:  Oncol Lett       Date:  2018-04-24       Impact factor: 2.967

10.  A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the "REal world dAta in LYmphoma and survival in adults" (REALYSA) cohort.

Authors:  Hervé Ghesquières; Cédric Rossi; Fanny Cherblanc; Sandra Le Guyader-Peyrou; Fontanet Bijou; Pierre Sujobert; Pascale Fabbro-Peray; Adeline Bernier; Aurélien Belot; Loic Chartier; Luc-Matthieu Fornecker; Isabelle Baldi; Krimo Bouabdallah; Camille Laurent; Lucie Oberic; Nadine Morineau; Steven Le Gouill; Franck Morschhauser; Corinne Haioun; Gandhi Damaj; Stéphanie Guidez; Gaëlle Labouré; Olivier Fitoussi; Laure Lebras; Rémy Gressin; Gilles Salles; Loïc Ysebaert; Alain Monnereau
Journal:  BMC Public Health       Date:  2021-03-02       Impact factor: 3.295

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.